Remus builds Latin American pipeline with 24 Bolivia tenders

In H1 FY27, Remus Pharmaceuticals Limited reported 1,805 registrations and applications in Latin America and the Caribbean, while securing tenders for 24 pharmaceutical products in Bolivia during the year. Remus is using this regulatory base, a Peru manufacturing-plant approval and planned semaglutide commercialisation to pursue institutional, distributor and own-brand sales.

What is Remus’s Latin American registration pipeline?

Remus’s largest regulatory portfolio is in Latin America and the Caribbean, where it reported 1,805 registrations and applications in H1 FY27. The region included 869 registered products and 936 products under registration, reflecting the company’s focus on markets where it already has institutional and distribution operations.

Across all markets, Remus reported 2,443 registrations and applications, comprising 955 registered products and 1,448 under registration. The stated global total is 40 products above the sum of those two categories, while the Latin America and Caribbean figures reconcile to the disclosed regional total.

ASEAN was the second-largest disclosed regional portfolio, with 406 registrations and applications, including 71 registered products and 335 under registration. Remus also cited 103 registrations and applications in Africa, 83 products in Eastern Europe and the Commonwealth of Independent States, or CIS, and 40 products in the Middle East.

How is Remus converting Bolivia and Peru filings into sales?

Remus is pursuing institutional sales in Bolivia after securing tenders covering 24 pharmaceutical products during the year. Management described Bolivia as one of its largest markets and said it aims to broaden its formulation portfolio alongside existing institutional and distribution relationships.

The 24 Bolivia tender awards offer a route from product registration to government procurement, rather than depending only on pharmacy-channel demand. Remus said it intends to pair its existing tender and distribution activity with a wider range of formulations in the market.

Peru is the next major market identified by management after its manufacturing plant received approval from the Peruvian authority in H1 FY27. Remus said it was filing 60 products in Peru and expected the plant approval to enable product approvals within four to six months.

Management said the 60 Peru filings could be commercialised in H2, subject to the regulatory process. The company did not disclose expected Peru revenue, the products being filed or individual launch dates, leaving the rate of conversion from filings to sales unresolved.

What is Remus doing in Venezuela and specialty therapies?

Remus expanded its Venezuela operations in H1 FY27 through a direct government tender, additional product registrations and approvals, and supply orders for new patch categories. The company launched one patch in the prior year and is preparing Rotigotine as its second patch launch in Venezuela and other Latin American markets.

Rotigotine adds to Remus’s central nervous system, or CNS, portfolio, where management said it is the first generic in the market. The company has initiated regulatory filings for more than 100 products in Venezuela and other markets, although it did not split that total by country.

Remus also in-licensed several molecules for Mexico, Chile, Vietnam and Peru, supported by bioequivalence studies. Management said these products would add to anti-infective and anti-allergy offerings, using manufacturing partnerships, regulatory capabilities and distribution networks to bring the molecules to market.

Remus received approval for semaglutide tablets and injections during H1 FY27 and said commercialisation was planned in the near term, probably in H2. Management said it sees opportunities in eligible international markets where there is no patent issue, rather than indicating launches across all of its more than 40 countries.

How is Remus expanding own-brand products and coverage?

Remus is building a business-to-consumer, or B2C, channel alongside its business-to-business, or B2B, operations through its own pharmaceutical brands. In H1 FY27, it received trademarks and brand approvals in the Dominican Republic and began introducing more than five own-label brands in Guatemala.

An investor said B2C contributed about 14% of H1 revenue and referred to a 25% to 30% contribution target. Management said B2C growth was in line with its commitments, but noted that building brands requires time and activity including medical samples, doctor visits, patient engagement and promotional packs.

Management said B2C gross margins could be 70% to 80%, while B2B margins were around 40%. It also said initial brand launches carry marketing and free-sample costs, meaning the B2C expansion is being pursued alongside, rather than instead of, B2B tenders and distributor sales.

Remus is also planning product registrations in Brazil, where management said it was selecting products and preparing regulatory filings with ANVISA. Beyond Latin America, it identified Africa, CIS and Eastern Europe for further expansion, while also highlighting Mexico and Chile as high-potential markets without providing submission or approval timetables.

Conclusion

Remus’s H1 FY27 activity shows an international model based on regulatory filings, institutional tender participation and a selective expansion into branded and specialty products. Its 1,805 Latin America and Caribbean registrations and applications, 24 Bolivia tender products, Peru filing programme and Rotigotine plans give it several possible paths from approvals to commercial sales.

The next developments to watch are management’s planned H2 commercialisation of the 60 Peru filings and approved semaglutide products, along with progress on more than 100 Venezuela and other-market filings. Brazil product selection and planned ANVISA filings, plus any conclusion of biosimilar in-licensing discussions, would show how Remus intends to extend this approach beyond its existing Latin American base.